×
Choose Speciality

EXPLORE!

LOGIN

Canagliflozin not associated with increased risk for fracture

  1041 Views

eMediNexus    02 January 2019

A study published in Annals of Internal Medicine found that compared with a glucagon-line peptide-1 (GLP-1) agonist, canagliflozin, an SGLT2 inhibitor, was not associated with an increased risk for fracture in middle-aged patients with type 2 diabetes and relatively low risk for fracture.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.